Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 17/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213077 | 0.91 | NPY5R (0.50) | NPY5RTACR1NOTUM | |
| SCHEMBL1997600 | 0.83 | NPY5R (0.69) | NPY5RTACR1 | |
| SCHEMBL1997601 | 0.83 | NPY5R (0.69) | NPY5RTACR1 | |
| Hydrochloric Acid SCHEMBL6214449 | 0.79 | NPY5R (0.40) | NPY5RTACR1NOTUMPDE4B | |
| SCHEMBL6212928 | 0.78 | NPY5R (0.49) | NPY5R | |
| SCHEMBL6212923 | 0.78 | NPY5R (0.49) | NPY5R | |
| SCHEMBL6216508 | 0.78 | NPY5R (0.49) | NPY5R | |
| SCHEMBL6216510 | 0.78 | NPY5R (0.49) | NPY5R | |
| SCHEMBL31396139 | 0.75 | NPY5R (0.48) | NPY5RTACR1NOTUM | |
| SCHEMBL6216136 | 0.70 | NPY5R (0.49) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129089-B1 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6638942-B1 | Useful in the treatment of obesity and the complications associated therewith. | MERCK & CO., INC. | 2003-10-28 | — | — | US | disclosed |
| EP-1129089-A4 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6495559-B2 | FOR THERAPY OF OBESITY | MERCK & CO., INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020058813-A1 | Spiro-indolines as Y5 receptor antagonists | MSD K.K. (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6313298-B1 | OBESITY, DIETETICS; NEUROPEPTIDE Y ANTAGONISTS | MERCK & CO., INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1129089-A1 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6191160-B1 | DIETETICS | MERCK & CO., INC. | 2001-02-20 | — | — | US | disclosed |
| WO-2000027845-A1 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058813-A1 | Spiro-indolines as Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | NPY5R 1/4885TACR1 61/4885NOTUM 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.